This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

Inclusion Criteria:

- Age > 30 years and ≤ 75 years with a diagnosis of type 2 diabetes mellitus made > 6
months prior to study entry

- Screening HbA1c > 7.0%

- Currently treated on a stable dose of at least 2 oral antidiabetic agents for at least
3 months prior to study entry; including a sulfonylurea and/or metformin, and/or a
thiazolidinedione

Exclusion Criteria:

Smoking within last 6 months PFTs outside of range

- Type 1 diabetes mellitus

- Type 2 diabetes mellitus currently (last three months) treated with an insulin regimen
(alone or with Oral Antidiabetic Agents)

- Active liver disease; significantly-impaired hepatic function, as shown by, but not
limited to, alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT)
or aspartate transaminase (AST) serum glutamic-oxaloacetic transaminase (SGOT) above
2x the upper limit of normal as measured at visit 1. However, patients with elevated
ALT >1.5 upper limit of normal as a result of hepatic steatosis are permitted to enter
the study.